(Q38968441)

https://doi.org/10.3892/ijo.2021.5280

8 September 2017

1 reference

29 December 2023

title

miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma (English)

1 reference

8 September 2017

Kai Liu

1

1 reference

8 September 2017

Songyang Liu

2

1 reference

8 September 2017

Wei Zhang

3

1 reference

8 September 2017

Bai Ji

4

1 reference

8 September 2017

Yingchao Wang

5

1 reference

8 September 2017

Yahui Liu

6

1 reference

8 September 2017

publication date

4 August 2014

1 reference

International Journal of Oncology

8 September 2017

published in

1 reference

8 September 2017

volume

45

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

1537-1546

1 reference

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation

8 September 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1016/J.CCR.2009.10.014

Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.

2 references

https://opencitations.net/index/api/v1/citations/10.1074/JBC.M111.270926

COCI

reference URL

30 December 2023

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Global cancer statistics

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

[Pitfalls in the classification of liver tumors]

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Multiple drug resistance mechanisms in cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Inhibition of translational initiation by Let-7 MicroRNA in human cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Management of hepatocellular carcinoma: An update

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Hepatocellular carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

The TNM staging system

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MicroRNA-mediated drug resistance in breast cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Sorafenib in advanced hepatocellular carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

MicroRNAs: small RNAs with big effects

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.3892/IJO.2014.2577

Identifiers

DOI

10.3892/IJO.2014.2577

1 reference

8 September 2017

1 reference